Table 1.
Basic characteristics of the two osteosarcoma groups
| Characteristics | Patients with pneumothorax (n = 14) |
Patients without pneumothorax (n = 40) |
P value |
|---|---|---|---|
| Gender | 1 | ||
| Male | 8 (57.14%) | 21 (52.50%) | |
| Female | 6 (42.86%) | 19 (47.50%) | |
| Age (years) | 22.00 ± 11.70 | 20.00 ± 9.80 | 0.564 |
| ECOG PS | 0.546 | ||
| 0 | 7 (50.00%) | 24 (60.00%) | |
| 1 | 7 (50.00%) | 16 (40.00%) | |
| Primary site | 0.973 | ||
| Femur | 5 (35.71%) | 13 (32.50%) | |
| Tibia | 3 (21.43%) | 11 (27.50%) | |
| Humerus | 3 (21.43%) | 6 (15.00%) | |
| Other | 1 (7.14%) | 4 (10.00%) | |
| Axial skeleton | 1 (7.14%) | 3 (7.50%) | |
| Radial | 1 (7.14%) | 1 (2.50%) | |
| Fibula | 0 (0.00%) | 2 (5.00%) | |
| Excision of primary lesion | 1 | ||
| No | 2 (14.29%) | 5 (12.50%) | |
| Yes | 12 (85.71%) | 35 (87.50%) | |
| Metastatic site | 0.681 | ||
| Only lung | 11 (78.57%) | 34 (85.00%) | |
| Both bone and lung | 3 (21.43%) | 6 (15.00%) | |
| Previous MAP/I chemotherapy | 1 | ||
| No | 1 (7.14%) | 5 (12.50%) | |
| Yes | 13 (92.86%) | 35 (87.50%) | |
| Time interval (months) | 4.36 ± 2.68 | 4.30 ± 2.41 | 0.504 |
| Apatinib dosage per administration (mg) | 435.46 ± 31.72 | 428.95 ± 33.87 | 1 |
Data are presented as numbers (percentages) or means ± SD.
ECOG PS, Eastern Cooperative Oncology Group performance status; MAP/I, high-dose methotrexate, doxorubicin, cisplatin, and/or ifosfamide; Time interval, time interval between the end of chemotherapy and oral apatinib administration.